Alimera Sciences, Inc. (ALIM)
Company Info
US0162592028
016259202
Apr 22, 2010
Highlights
$301.29M
$1.05
5.28
$27.00M
$20.08M
$3.03M
$2.77 - $5.65
$5.67
3.03%
1.93
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Alimera Sciences, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
ALIM
N/A
N/A
N/A
N/A
N/A
N/A
^GSPC (Benchmark)
-3.70%
13.67%
-5.18%
9.18%
14.14%
10.43%
Monthly Returns
The table below presents the monthly returns of ALIM, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -15.51% | -3.01% | 10.17% | -5.64% | -17.12% | 82.30% | 0.00% | -0.54% | 0.18% | 28.24% | |||
| 2023 | -0.37% | -20.37% | -2.33% | -12.86% | 50.27% | 6.18% | 16.78% | -3.52% | -5.78% | 8.06% | -7.91% | 40.03% | 59.41% |
| 2022 | -11.89% | 7.52% | 15.23% | 0.54% | 8.35% | -10.33% | 4.39% | 18.39% | -24.85% | 2.76% | -33.91% | -21.45% | -47.17% |
| 2021 | 59.24% | 20.09% | 19.21% | 6.44% | 2.54% | -13.33% | -2.97% | -32.16% | -29.55% | 4.74% | 18.33% | -1.91% | 21.56% |
| 2020 | -13.06% | 9.41% | -44.52% | 35.00% | -6.87% | 25.27% | -6.83% | 0.68% | -17.77% | -12.65% | 10.48% | -10.02% | -44.33% |
| 2019 | 36.43% | 18.40% | -8.62% | -8.49% | -9.28% | 1.14% | -44.94% | -15.10% | 36.13% | -49.96% | 33.15% | 33.92% | -29.63% |
| 2018 | -12.03% | 11.11% | -20.77% | 8.74% | -30.00% | 24.78% | 8.35% | -1.89% | -5.77% | 2.55% | 1.49% | -29.60% | -46.01% |
| 2017 | 7.41% | 11.21% | 8.53% | 14.29% | -11.25% | -2.11% | 3.60% | -3.47% | -2.88% | -8.89% | 6.10% | 1.92% | 23.15% |
| 2016 | -4.55% | -6.93% | -18.60% | 26.86% | -30.63% | -20.13% | 66.67% | -25.37% | -2.61% | -16.11% | -12.00% | -1.82% | -55.37% |
| 2015 | -1.99% | -3.68% | -4.21% | -12.97% | -2.98% | 8.98% | 4.56% | -30.71% | -33.83% | 36.20% | 2.33% | -21.43% | -56.32% |
| 2014 | 35.53% | 5.34% | 17.59% | -22.94% | -1.81% | 0.17% | -3.34% | 8.82% | -13.83% | 5.17% | 2.98% | -5.62% | 17.87% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of ALIM is 75, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Alimera Sciences, Inc. (ALIM) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Alimera Sciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Alimera Sciences, Inc. was 99.26%, occurring on Mar 22, 2023. The portfolio has not yet recovered.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.26% | Nov 26, 2010 | 3100 | Mar 22, 2023 | — | — | — |
| -40.14% | Apr 29, 2010 | 54 | Jul 15, 2010 | 77 | Nov 2, 2010 | 131 |
| -10.42% | Nov 3, 2010 | 4 | Nov 8, 2010 | 10 | Nov 22, 2010 | 14 |
| -0.32% | Apr 27, 2010 | 1 | Apr 27, 2010 | 1 | Apr 28, 2010 | 2 |
Volatility
Volatility Chart
The current Alimera Sciences, Inc. volatility is 9.53%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Alimera Sciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Alimera Sciences, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -50.0%.
Valuation
The Valuation section provides an overview of how Alimera Sciences, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for ALIM, comparing it with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, ALIM has a P/E ratio of 5.3. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for ALIM compared to other companies in the Drug Manufacturers - Specialty & Generic industry. ALIM currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ALIM relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, ALIM has a P/S ratio of 3.0. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ALIM in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, ALIM has a P/B value of 7.8. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |